Capecitabineand mitomycin C (MMC) is an active regimen for patients with metastatic colorectal carcinoma (MCRC) resistant to 5FU and irinotecan

被引：0
|
作者：
Rao, S [1 ]
Cunningham, D [1 ]
Ross, PJ [1 ]
Price, T [1 ]
Ward, C [1 ]
Norman, AR [1 ]
Hill, ME [1 ]
机构：
[1] Royal Marsden Hosp, Sutton SM2 5PT, Surrey, England
来源：
BRITISH JOURNAL OF CANCER | 2003年 / 88卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S56 / S56
页数：1
相关论文
共 50 条
  • [1] INTRAHEPATIC ARTERIAL INFUSION WITH COMBINATION OF MITOMYCIN-C (MMC) AND 5-FLUOROURACIL (5FU) FOR TREATMENT OF PRIMARY AND METASTATIC CARCINOMA OF LIVER
    MISRA, N
    JAISWAL, M
    SINGH, R
    DAS, B
    PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1974, 15 (MAR): : 113 - 113
  • [2] A simplified bi-monthly regimen with leucovorin (LV) and 5-Fluorouracil (5FU) for metastatic colorectal cancer (MCRC)
    Tournigand, C
    de Gramont, A
    Louvet, C
    Andre, T
    Carola, E
    Gilles-Amar, V
    Maindrault-Goebel, F
    Lotz, JP
    Molitor, JL
    ANNALS OF ONCOLOGY, 1998, 9 : 40 - 40
  • [3] Capecitabine and mitomycin C in patients with metastatic colorectal cancer resistant to fluorouracil and irinotecan
    Alliot, C
    BRITISH JOURNAL OF CANCER, 2006, 94 (06) : 935 - 936
  • [4] Capecitabine and mitomycin C in patients with metastatic colorectal cancer resistant to fluorouracil and irinotecan
    C Alliot
    British Journal of Cancer, 2006, 94 : 935 - 936
  • [5] COMBINATION CHEMOTHERAPY WITH 5FU INFUSION IN METASTATIC COLORECTAL CARCINOMA
    RATKIN, G
    PRESANT, CA
    ZEFFREN, JL
    PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1977, 18 (MAR): : 322 - 322
  • [6] Capecitabine versus 5FU in association with oxaliplatin or CPT11 in metastatic colorectal carcinoma (MCRC) patients: Compliance and toxicity
    Di Seri, M.
    Ricciardi, S.
    Messina, C.
    Rossi, L.
    Rosati, S.
    Spalletta, B.
    Cerbone, L.
    Russillo, M.
    Manna, A.
    Iongo, F.
    ANNALS OF ONCOLOGY, 2006, 17 : 69 - 69
  • [7] Phase II trial of 5-fluorouracil (5FU)/leucovorin (LV), irinotecan, and oxaliplatin (FOLFOXIRI) plus cetuximab in patients with metastatic colorectal cancer (mCRC).
    Sougklakos, I.
    Vardakis, N. K.
    Kampouraki, E.
    Kotortsi, I.
    Androulakis, N. E. M.
    Vamvakas, L.
    Kalbakis, K.
    Hatzidaki, D.
    Mavroudis, D.
    Georgoulias, V.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [8] Reply: Capecitabine and mitomycin C in patients with metastatic colorectal cancer resistant to fluorouracil and irinotecan
    G Chong
    D Cunningham
    British Journal of Cancer, 2006, 94 : 937 - 937
  • [9] Reply: Capecitabine and mitomycin C in patients with metastatic colorectal cancer resistant to fluorouracil and irinotecan
    Chong, G
    Cunningham, D
    BRITISH JOURNAL OF CANCER, 2006, 94 (06) : 937 - 937
  • [10] SUNCAP, a phase II study with sunitinib and capecitabine in patients with metastatic colorectal cancer (MCRC) refractory to previous treatment with 5FU/irinotecan/oxaliplatin.
    Samson, B.
    Latreille, J.
    Nguyen, N. T.
    Sperlich, C.
    Berbiche, D.
    Tournigand, C.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (04)
12345